相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma
J. P. Laubach et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
The activated conformation of integrin β7 is a novel multiple myeloma-specific target for CAR T cell therapy
Naoki Hosen et al.
NATURE MEDICINE (2017)
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
Jakub Krejcik et al.
CLINICAL CANCER RESEARCH (2017)
Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma
Ashraf Badros et al.
BLOOD (2017)
Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication
Gang An et al.
BLOOD (2016)
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
Syed Abbas Ali et al.
BLOOD (2016)
Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 trial
Antonin Levy et al.
EUROPEAN JOURNAL OF CANCER (2016)
Clinical responses with T lymphocytes targeting malignancy-associated κ light chains
Carlos A. Ramos et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
Alexander M. Lesokhin et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Sagar Lonial et al.
LANCET (2016)
Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade
H. Suen et al.
LEUKEMIA (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1
Mariko Ishibashi et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy
Madhav V. Dhodapkar et al.
BLOOD (2015)
Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma
Guellue Goerguen et al.
CLINICAL CANCER RESEARCH (2015)
PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma
B. Paiva et al.
LEUKEMIA (2015)
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
Adrienne H. Long et al.
NATURE MEDICINE (2015)
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
Alfred L. Garfall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Sagar Lonial et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Immune impairments in multiple myeloma bone marrow mesenchymal stromal cells
Thibaud Andre et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy
Anne-Marit Sponaas et al.
PLOS ONE (2015)
Genetic Modification of T Cells Redirected toward CS1 Enhances Eradication of Myeloma Cells
Jianhong Chu et al.
CLINICAL CANCER RESEARCH (2014)
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Jan Kroenke et al.
SCIENCE (2014)
CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma
Monica Casucci et al.
BLOOD (2013)
Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients
Jacalyn Rosenblatt et al.
CLINICAL CANCER RESEARCH (2013)
Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry
Roberto J. Pessoa de Magalhaes et al.
HAEMATOLOGICA (2013)
Myeloid-Derived Suppressor Cells Regulate Growth of Multiple Myeloma by Inhibiting T Cells in Bone Marrow
Indu R. Ramachandran et al.
JOURNAL OF IMMUNOLOGY (2013)
Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma
H. Tamura et al.
LEUKEMIA (2013)
Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance
C. Bryant et al.
BLOOD CANCER JOURNAL (2013)
A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
Jeffrey A. Zonder et al.
BLOOD (2012)
Inhibition of NKG2D expression in NK cells by cytokines secreted in response to human cytomegalovirus infection
Aura Muntasell et al.
BLOOD (2010)
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
Don M. Benson et al.
BLOOD (2010)
Idiotype-pulsed antigen presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival
Martha Q. Lacy et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
A novel immunoregulatory axis of NKT cell subsets regulating tumor immunity
Jay A. Berzofsky et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
TGF-β utilizes SMAD3 to inhibit CD16-mediated IFN-γ production and antibody-dependent cellular cytotoxicity in human NK cells
Rossana Trotta et al.
JOURNAL OF IMMUNOLOGY (2008)
The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells
Yasser M. El-Sherbiny et al.
CANCER RESEARCH (2007)
Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway
Jizhong Liu et al.
BLOOD (2007)
Immunodeficiency and immunotherapy in multiple myeloma
Guy Pratt et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-γ-induced upregulation of B7-H1 (CD274)
SJ Lee et al.
FEBS LETTERS (2006)
Dendritic cell-tumor fusion vaccines for renal cell carcinoma
D Avigan
CLINICAL CANCER RESEARCH (2004)
Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy
MV Dhodapkar et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma
MV Dhodapkar et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
HD Dong et al.
NATURE MEDICINE (2002)
分享论文
